NCT02994732View on ClinicalTrials.gov

Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

February 28, 2017

Study Completion Date

May 15, 2017

Conditions

Healthy

Interventions

DRUG

[14C]-BVD-523

\[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.